Our results suggest a novel regulatory mechanism contributing to the high protein expression levels of c-MET in HCC, implicating ASAP2 as a potent therapeutic target for treating c-MET-activated HCC. This evidence concerns the gene ASAP2 and hepatocellular carcinoma.